Global Pre-Menstrual Syndrome Market Growth (Status and Outlook) 2025-2031

According to this study, the global Pre-Menstrual Syndrome market size will reach US$ million by 2031.

Pre-menstrual syndrome (PMS) is defined as a condition that affects women at childbearing age and is characterized by symptoms such as bloating, pain, breast tenderness, body pain, fatigue, mood fluctuation, anxiety, etc.

United States market for Pre-Menstrual Syndrome is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Pre-Menstrual Syndrome is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Pre-Menstrual Syndrome is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Pre-Menstrual Syndrome players cover Alva-Amco Pharmacal Cos., Inc., Bayer, Inc., Chattem, Inc. (Sanofi), DEKK-TEC, Inc., G. R. Lane Health Products Ltd, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Pre-Menstrual Syndrome Industry Forecast” looks at past sales and reviews total world Pre-Menstrual Syndrome sales in 2024, providing a comprehensive analysis by region and market sector of projected Pre-Menstrual Syndrome sales for 2025 through 2031. With Pre-Menstrual Syndrome sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Pre-Menstrual Syndrome industry.

This Insight Report provides a comprehensive analysis of the global Pre-Menstrual Syndrome landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Pre-Menstrual Syndrome portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Pre-Menstrual Syndrome market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Pre-Menstrual Syndrome and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Pre-Menstrual Syndrome.

This report presents a comprehensive overview, market shares, and growth opportunities of Pre-Menstrual Syndrome market by product type, application, key players and key regions and countries.

Segmentation by Type:
Analgesics (Pain Killers)
Oral Contraceptive Pills (OCPs)
Gonadotropin-Releasing Hormone (GnRH)
Antidepressants
Ovarian Suppressors
Diuretics
Benzodiazepines

Segmentation by Application:
Hospitals
Clinic
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Alva-Amco Pharmacal Cos., Inc.
Bayer, Inc.
Chattem, Inc. (Sanofi)
DEKK-TEC, Inc.
G. R. Lane Health Products Ltd
McNeil Consumer Healthcare
MetP Pharma AG
Pherin Pharmaceuticals, Inc.
Umecrine Mood AB
Novartis AG
GlaxoSmithKline Plc

Please note: The report will take approximately 2 business days to prepare and deliver. Show more